MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: MDxHealth, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth and Exact Sciences Sign Collaboration Agreement - Exact Sciences also to acquire biomarker and technology patents [Nasdaq: EXAS] - ExactSciences.com / MDxHealth.com
MDxHealth and Exact Sciences Sign Collaboration Agreement

 

NewswireToday - /newswire/ - Irvine, CA, United States, 2017/04/27 - Exact Sciences also to acquire biomarker and technology patents [Nasdaq: EXAS] - ExactSciences.com / MDxHealth.com. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MDxHealth SA today announced that it has signed a five-year agreement with Exact Sciences Corp. for collaboration in the growing field of epigenetics and molecular diagnostics.

Building on a long-standing relationship spanning more than a decade, the new agreement will allow MDxHealth and Exact Sciences to share proprietary technologies arising from their respective ground-breaking discovery and development efforts in the fields of epigenetics and molecular diagnostics. Over the course of the collaboration, the parties may identify opportunities to share technologies in a range of indications, including urologic and lung cancers.

Contemporaneously with the execution of the collaboration agreement, Exact Sciences is also acquiring MDxHealth patents directed toward colorectal cancer, including its DNA methylation biomarker, NDRG4, as well as technology covering the use of FIT (fecal immunochemical test) in combination with methylation. These acquisitions include one-time fees totaling $15 million, including payments accrued since July 2016.

"With its ground-breaking achievements in molecular diagnostics, Exact Sciences is an ideal partner for us to collaborate with in the identification and development of new biomarkers for clinical diagnostic products," said Prof. Dr. Wim van Criekinge, CSO of MDxHealth. "The collaboration may allow each party to better capitalise on its cutting-edge epigenetic research and development efforts to bring new products and services to market to improve patient lives."

"MDxHealth has established itself as a leader in the discovery and development of epigenetic and molecular diagnostics technologies, particularly in the field of urology," said Dr. Graham Lidgard, CSO and SVP of R&D of Exact Sciences. "We are delighted to continue our long-standing scientific co-operation through this new agreement, which has the potential to benefit both companies' product development programs."

About MDxHealth

MDxHealth (mdxhealth.com) is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

About Exact Sciences

Exact Sciences Corp. (exactsciences.com) is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


MDxHealth and Exact Sciences Sign Collaboration Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Shalon Roth - MDxHealth.com 
+44(0)73 9390 6278 info[.]mdxhealth.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From MDxHealth, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Huntington Study Group Ltd





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)